Paper: Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab
Program: O ral and Poster Abstracts Type: Oral Session: 907. Outcomes Research: Plasma Cell Disorders: Bispecific Antibodies and CAR-T Therapies in Myeloma-The Yin and Yang of Powerful Therapies Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Diseases, Treatment Considerations, Lymphoid Malignancies, Adverse Events Andrew Kowalski, PharmD 1 *, Jill Lykon, PharmD 2 *, Benjamin Diamond, MD 2, David G. Coffey, MD 2, Marcella Kaddoura, MD 3,
